Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Phase of Trial: Phase IV
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Nilotinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms SUSTRENIM
- 16 Oct 2017 Status changed from not yet recruiting to recruiting.
- 13 Sep 2016 Planned initiation date changed from 1 Mar 2016 to 1 Dec 2016.
- 24 Feb 2016 Planned End Date changed from 1 Feb 2021 to 1 Feb 2024 as reported by ClinicalTrials.gov record.